When did the Nurix Therapeutics (NRIX) insider share sale take place?

The insider sale by Chief Legal Officer Christine Ring occurred on May 1, 2026. All reported trades on that date are included in the Form 4, aggregated into a single weighted average sale price with a specified price range.

Nurix Therapeutics (NRIX) legal chief sells 5,394 shares in planned trade

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 5,394 shares of common stock on May 1, 2026 at a weighted average price of $16.7606 per share. The sale was executed under a previously adopted Rule 10b5-1 trading plan, with individual sale prices ranging from $16.26 to $16.97. Following this transaction, she directly holds 26,453 shares of Nurix common stock.

Insider Trade Summary 10b5-1

Net Seller: 5,394 shares ($90,407)

Net Sell 1 txn

Insider Ring Christine

Role Chief Legal Officer

Sold 5,394 shs ($90K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,394	$16.7606	$90K

Holdings After Transaction: Common Stock — 26,453 shares (Direct, null)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $16.26 and the highest price at which shares were sold was $16.97. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Shares sold: 5,394 shares Weighted average sale price: $16.7606 per share Post-transaction holdings: 26,453 shares +2 more

5 metrics

Shares sold 5,394 shares Open-market sale by Chief Legal Officer

Weighted average sale price $16.7606 per share Common stock sale on May 1, 2026

Post-transaction holdings 26,453 shares Direct ownership after sale

Low sale price $16.26 per share Lowest price within reported sale range

High sale price $16.97 per share Highest price within reported sale range

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold"

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 05:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		S⁽¹⁾		5,394	D	$16.7606⁽²⁾	26,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.26 and the highest price at which shares were sold was $16.97. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Nurix Therapeutics (NRIX) report for Christine Ring?

Nurix Therapeutics reported that Chief Legal Officer Christine Ring sold 5,394 shares of common stock in an open-market transaction. The sale was executed under a previously adopted Rule 10b5-1 trading plan, providing for pre-arranged trades over time.

At what price did Christine Ring sell Nurix Therapeutics (NRIX) shares?

Christine Ring’s sale used a weighted average price of $16.7606 per Nurix Therapeutics share. Individual trades occurred between $16.26 and $16.97, reflecting multiple executions within that range on the same trading day.

How many Nurix Therapeutics (NRIX) shares does Christine Ring hold after the sale?

After the reported transaction, Chief Legal Officer Christine Ring directly holds 26,453 shares of Nurix Therapeutics common stock. This figure reflects her position immediately following the open-market sale disclosed in the Form 4 filing.

Was the Nurix Therapeutics (NRIX) insider trade made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by Christine Ring. Such plans pre-schedule trades, which can reduce the informational significance of the transaction’s exact timing for investors.

What does the weighted average price mean in the Nurix Therapeutics (NRIX) Form 4?

The weighted average price of $16.7606 means multiple trades occurred at different prices between $16.26 and $16.97. The average is calculated based on the number of shares sold at each price, and detailed breakdowns are available on request.